Steris Plc has delivered a strong financial performance with notable revenue growth in Q3 2025, earning an adjusted EPS of $2.32, surpassing expectations. This progress has contributed to a pleasing share return of 42% and 51% over five and three years, respectively. Despite ongoing macro issues and stronger dollar conditions that led to lowered annual profit forecasts, Steris continues to exhibit resilience with strategic acquisitions and expanded product offerings. The company has also maintained its quarterly interim dividend at $0.57 per share, indicating financial stability. The recently reported sale of its renal care business and dental segment indicates a shift in strategy, possibly to focus more on core operations. Management's confidence is reflected in clues of a CEO succession plan underway. While some investors have offloaded their shares, others are expanding their stake in Steris, signaling a mixed response among stakeholders. Nevertheless, Wall Street analysts seem to favor Steris, with Piper Sandler increasing the stock price target to $265.
Steris Plc STE News Analytics from Wed, 24 Jun 2015 07:00:00 GMT to Sat, 08 Feb 2025 11:43:19 GMT -
Rating 7
- Innovation 5
- Information 9
- Rumor 3
